Form 4: OptiNose Director Eric Bednarski Granted Stock Options

Director Eric Bednarski of OptiNose, Inc. was granted stock options to purchase 75,000 shares of common stock.

Summary

• On June 6, 2024, Eric Bednarski, a director of OptiNose, Inc., was granted stock options to purchase 75,000 shares of the company's common stock at an exercise price of $1.04 per share.
• The options vest on the earlier of June 6, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service with the Issuer.
• Following this transaction, Mr. Bednarski directly owns derivative securities consisting of 75,000 stock options.

Sentiment

Score: 6

Explanation: The document reflects a standard executive compensation practice. It's neutral in sentiment, indicating routine corporate governance.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning management's interests with increasing shareholder value.
• Employees may view the granting of stock options to leadership as a positive sign of the company's commitment to its team.

Key Dates